Clarity Pharmaceuticals (CU6) - FDA No-Go for Y-MAb’s Neuroblastoma Drug

300 Views12 Nov 2022 06:56
Broker
The negative outcome isn’t the first for Y-mAbs. The BLA for omburtamab was originally submitted to the FDA in August 2020.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Wilsons Advisory
External broker reports(aggregated public sources)
Wilsons Advisory
AustraliaEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x